Menu
Search
|

Menu

Close
X

GW Pharmaceuticals PLC GWPH.OQ (NASDAQ Stock Exchange Global Market)

163.00 USD
-3.24 (-1.95%)
As of Jul 17
Previous Close 166.24
Open 167.00
Volume 100,464
3m Avg Volume 101,893
Today’s High 167.00
Today’s Low 161.52
52 Week High 196.00
52 Week Low 90.20
Shares Outstanding (mil) 2.11
Market Capitalization (mil) 2,789.42
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY19
39
FY18
14
FY17
10
FY16
15
EPS (USD)
FY19
-0.135
FY18
-0.566
FY17
-0.552
FY16
-0.336
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
275.00
7.92
Price to Book (MRQ)
vs sector
6.72
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
1.59
14.56
LT Debt to Equity (MRQ)
vs sector
1.52
10.21
Return on Investment (TTM)
vs sector
-38.35
14.49
Return on Equity (TTM)
vs sector
-41.13
15.79

EXECUTIVE LEADERSHIP

Geoffrey Guy
Executive Chairman of the Board, Since
Salary: $339,305.00
Bonus: --
Justin Gover
Chief Executive Officer, Director, Since 1999
Salary: $279,296.00
Bonus: --
James Noble
Non-Executive Deputy Chairman of the Board, Senior Independent Director, Since 2007
Salary: $61,984.00
Bonus: --
Adam George
Chief Financial Officer, Company Secretary, Director, Since 2012
Salary: $189,163.00
Bonus: --
Christopher Tovey
Chief Operating Officer, Executive Director, Since 2012
Salary: $205,370.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Sovereign House
Vision Park, Chivers Way
CAMBRIDGE     CB24 9BZ

Phone: +441223.266800

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company is also focused on developing its pharmaceutical product pipelines, which includes Epidiolex for the treatment of Tuberous Sclerosis Complex and RETT Syndrome.

SPONSORED STORIES